Introduction The study aimed to evaluate the efficacy of a combination therapy (isatuximab, carfilzomib, lenalidomide, and dexamethasone, referred to as Isa-KRd) in patients with newly diagnosed multiple myeloma (NDMM) who are classified as high-risk. High-risk patients often have poor outcomes, and achieving minimal residual disease (MRD) negativi
Pancytopenia, a rare presentation of hyperthyroidism
830 Reached2 Comments
Safe Ramadan Practices during COVID-19 - WHO Guidance
4873 Reached8 Comments3 Likes
How Physicians Should Manage Stress?
35294 Reached152 Comments203 Likes
Managing Meconium Aspiration Syndrome in Infants
9817 Reached7 Comments8 Likes
Infant with Congenital Diaphragmatic Hernia (CDH)
6967 Reached14 Comments8 Likes